According to filings with the U.S. Securities and Exchange Commission, Convergent Therapeutics is raising up to $39,999,996.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Philip Kantoff played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Convergent Therapeutics
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

To learn more about Convergent Therapeutics, visit http://convergentrx.com/
Convergent Therapeutics Linkedin Page: https://www.linkedin.com/company/convergent-therapeutics/

Contact:
Philip Kantoff, Chief Executive Officer
617-710-4289

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.